| Dr Mark Drury Ghegan, MD | |
|
1849 Savage Rd, Charleston, SC 29407-4726 | |
| (843) 766-7103 | |
| (843) 763-3834 |
| Full Name | Dr Mark Drury Ghegan |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 21 Years |
| Location | 1849 Savage Rd, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043308448 | NPI | - | NPPES |
| 258296 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 060840 (Georgia) | Secondary |
| 207Y00000X | Otolaryngology | 25829 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Pleasant Hospital | Mount pleasant, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Charleston Ent Associates, Llc | 4082662234 | 64 |
News Archive
Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting on June 14.
QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.
People with severe depression are constantly despondent, lacking in drive, withdrawn and no longer feel joy. Most suffer from anxiety and the desire to take their own life. Approximately one out of every five people in Germany suffers from depression in the course of his/her life - sometimes resulting in suicide. People with depression are frequently treated with psychotherapy and medication.
› Verified 3 days ago
| Entity Name | Charleston Ent Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588607303 PECOS PAC ID: 4082662234 Enrollment ID: O20050105000267 |
News Archive
Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting on June 14.
QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.
People with severe depression are constantly despondent, lacking in drive, withdrawn and no longer feel joy. Most suffer from anxiety and the desire to take their own life. Approximately one out of every five people in Germany suffers from depression in the course of his/her life - sometimes resulting in suicide. People with depression are frequently treated with psychotherapy and medication.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Drury Ghegan, MD 1849 Savage Rd, Charleston, SC 29407-4726 Ph: (843) 766-7103 | Dr Mark Drury Ghegan, MD 1849 Savage Rd, Charleston, SC 29407-4726 Ph: (843) 766-7103 |
News Archive
Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting on June 14.
QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.
People with severe depression are constantly despondent, lacking in drive, withdrawn and no longer feel joy. Most suffer from anxiety and the desire to take their own life. Approximately one out of every five people in Germany suffers from depression in the course of his/her life - sometimes resulting in suicide. People with depression are frequently treated with psychotherapy and medication.
› Verified 3 days ago
Jenna Hanner Barengo, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Charleston, SC 29425 Phone: 740-525-0170 | |
Ronald James Mcvicar, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1849 Savage Rd, Charleston, SC 29407 Phone: 843-766-7103 Fax: 843-576-2692 | |
Nicole Kloosterman, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 135 Rutledge Ave # Msc550, Charleston, SC 29425 Phone: 843-792-8299 | |
Anthony Ghanem, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 135 Rutledge Ave Ste 1130, Charleston, SC 29425 Phone: 843-876-0791 Fax: 843-792-0546 | |
Dr. David Watson Rodwell Iii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 67 Broad St, Suite 200, Charleston, SC 29401 Phone: 843-628-1415 | |
Ted Meyer, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 |